Company profile
Nektar Therapeutics
NASDAQ: NKTR · Healthcare · Biotechnology
#418 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
50DFH 34DQ 80GM 25SS 79
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$55.6M
Rev growth YoY (TTM)
-36.2%
Net income (FY)
-$164.1M
Employees
63
as of 2026-08-10
Market cap
$2.2B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$55.2M$55.2M2025
Net income-$164.1M-$164.1M2025
Operating income-$140.1M-$140.1M2025
Total assets$280.4M$280.4M2025
Liabilities$190.6M$190.6M2025
Equity$89.8M$89.8M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Non Cash Royalty Revenue Related To Sale Of Future Royalties99%
License Collaboration And Other Revenue1%
By geography
Non-US100%
The read
What is Nektar Therapeutics’s revenue?
Nektar Therapeutics booked $55.2M in FY2025 revenue, contracting 44% year over year — slower than 80% of Healthcare companies we track, at a -297.1% net margin.
Peers · Healthcare
CVRx, Inc.50DHLS Therapeutics Inc.64C908 Devices Inc.60CThe Joint Corp.75B+Integrated BioPharma, Inc.67BAgios Pharmaceuticals, Inc.70BNeighbors
San Francisco →Key facts
CEOHoward W. Robin
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Francisco, CA
ExchangeNASDAQ: NKTR
Employees63
IPO date1994-05-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.